Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Danaher Corporation
  6. Summary
    DHR.PRB   US2358514097

DANAHER CORPORATION

(DHR.PRB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
0(c) 1584.13(c) 1581.76(c) 1608.07(c) 1610.75(c) Last
103 1 443 13 043 659 793 Volume
-0.15% +1.66% +0.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 28 701 M - -
Net income 2021 6 124 M - -
Net Debt 2021 15 197 M - -
P/E ratio 2021 36,4x
Yield 2021 0,30%
Sales 2022 30 353 M - -
Net income 2022 6 150 M - -
Net Debt 2022 10 555 M - -
P/E ratio 2022 36,4x
Yield 2022 0,33%
Capitalization 215 B 215 B -
EV / Sales 2021 8,03x
EV / Sales 2022 7,44x
Nbr of Employees 68 000
Free-Float 74,2%
More Financials
Company
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through three segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies... 
More about the company
Ratings of Danaher Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about DANAHER CORPORATION
10/12DANAHER : Releases 2021 Sustainability Report; Building A Strong Foundation Of Sustainabil..
PR
09/29DANAHER CORPORATION : Ex-dividend day for
FA
09/28DANAHER : Beckman Coulter's new urinalysis solution improves laboratory workflow by signif..
PR
09/21DANAHER : Schedules Third Quarter 2021 Earnings Conference Call
PR
09/15DANAHER CORP /DE/ : Change in Directors or Principal Officers, Financial Statements and Ex..
AQ
09/14DANAHER : Keeps Quarterly Cash Dividend Unchanged at $0.21 a Share, Payable Oct. 29 to Sha..
MT
09/14DANAHER : Announces Quarterly Dividends
PR
09/14Danaher Corporation Approves Regular Quarterly Cash Dividend, Payable on October 29, 20..
CI
09/10DANAHER : Credit Suisse Raises Danaher's PT to $370 from $306, Notes Heightened Conviction..
MT
09/08DANAHER : RBC Raises Price Target on Danaher to $332 From $304 Ahead of Analyst Day, Maint..
MT
09/03DANAHER : Helping Customers Make Better Beer -- and Improve Sustainability
PU
09/01SCIEX : Presents Industry First Multi-Capillary System for CE-SDS, the BioPhase 8800 Syste..
BU
09/01SCIEX : Builds on Cadence of Innovation in Biopharma With Biologics Explorer
BU
08/30DANAHER : Closes $9.6 Billion Acquisition Deal for Aldevron
MT
08/30DANAHER : Completes Acquisition of Aldevron
PR
More news
News in other languages on DANAHER CORPORATION
09/14Danaher Corporation approuve un dividende trimestriel régulier en espèces, payable le 2..
09/13Deux valeurs dans la santé qui mériteraient d'être plus connues
08/11LE TOUR D’HORIZON DES ETF : Quatre produits à objectifs vertueux
04/22STOCK MARKET PARIS : Biden, Lagarde et un déluge de publications
04/22EN DIRECT DES MARCHESá : Renault, Hermès, Orange, Pernod Ricard, Ipsen, Nestlé, Crédit Sui..
More news
Analyst Recommendations on DANAHER CORPORATION
More recommendations
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | DHR.PRB | US2358514097 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 301,38 $
Average target price 324,76 $
Spread / Average Target 7,76%
EPS Revisions
Managers and Directors
Rainer M. Blair President, Chief Executive Officer & Director
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Steven M. Rales Chairman
Jose Carlos GutiÚrrez Ramos Chief Science Officer & Senior Vice President
Brian W. Ellis Senior Vice President & General Counsel
Sector and Competitors